ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

/in

Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 Triple mode of action dengue fever program identified for development Industry veteran with exceptional leadership experience to support ExeVir’s new progressive pipeline against infectious diseases  Ghent, Belgium, 20 Oct 2022: ExeVir is developing robust therapies providing broad protection […]

Read more

AMSilk Relocate Offices to Support Expansion Plans

/in

The purpose-built offices will support its production of game-changing material solutions on an industrial scale Expanding biotech laboratory, pilot plants and office space, AMSilk embarks on the next stage of its journey to provide biofabricated silk materials across the world Munich, Germany, 10 October 2022 – AMSilk GmbH (“AMSilk”), a world leader in supplying innovative high-performance […]

Read more

Neuraxpharm launches European campaign to increase awareness of medical cannabis

/in

Neuraxpharm launches European campaign to increase awareness of medical cannabis On the occasion of the German Pain Congress 2022 (Deutscher Schmerzkongress 2022) the CNS-specialist announces Change for Health campaign Düsseldorf and Barcelona, October 19, 2022 – Neuraxpharm, a leading European specialty pharmaceutical company, today announces its “Change for Health” campaign that aims to increase the acceptance […]

Read more

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

/in

AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® metal-free click chemistry. Read more…

Read more

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

/in

Non-dilutive capital finances planned launch of ensifentrine for COPD LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt facility”) providing the Company with access to up to $150 million from Oxford Finance LLC (“Oxford”). […]

Read more
© Optimum Strategic Communications.